ArticleThe Journal of infectious diseases2026
From Skin to Sequence: Pan-species Detection and Speciation of Leishmania.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of Recombinase Polymerase Amplification and CRISPR-Cas12a-Enhanced Isothermal Amplification Assays for Strongyloides stercoralis DNA Detection: A Pilot Study.The American journal of tropical medicine and hygiene · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLeishmaniasis remains a significant public health concern. Accurate and efficient diagnostic methods are crucial for timely intervention and management. The limitations of current diagnostic approaches necessitated the exploration of novel targets and tools. This study describes 2 tandemly repeated sequences within the Leishmania genome that allow for sensitive and specific pan-Leishmania detection and speciation via quantitative polymerase chain reaction (qPCR) and recombinase polymerase amplification (RPA) and sequencing.
methodsThrough bioinformatic analysis of highly repeated elements of all Leishmania sp genomes, pan-Leishmania qPCR targets (CL3 and CL179) were identified and validated by qPCR. Amplicons from an RPA-based assay for CL179 qPCR with DNA from clinical samples were sequenced by nanopore sequencing.
resultsThe limits of detection for CL3 and CL179 qPCRs were ∼96 and ∼217 fg of genomic DNA across available Leishmania spp known to infect humans. The CL3 and CL179 qPCR could detect a single L donovani-infected macrophage. When tested with DNA extracted from skin biopsies (n = 8) and swabs (n = 7) from patients confirmed positive by 18S qPCR, CL3 and CL179 exhibited 100% sensitivity. Microbiopsies (n = 9) were also positive, with sensitivities of 88% and 67% for CL3 and CL179 qPCRs, respectively. Nanopore sequencing of RPA products resulted in the accurate speciation of Leishmania strains in patients confirmed to have leishmaniasis.
conclusionsCL3 and CL179 demonstrated high sensitivity and specificity, showing no cross-reactivity with related parasitic intracellular protists. Our data provide an ultrasensitive approach to the rapid diagnosis and subsequent speciation of all Leishmania strains known to infect humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.